A Single-arm, Open-label, Single-center Clinical Study: Safety and Efficacy of Anti-CD7 CAR-T in the Treatment of Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Latest Information Update: 27 Jul 2023
At a glance
- Drugs Anti-CD7-CAR-T-cell-therapy-Guangzhou-Bio-gene-Technology (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Guangzhou Bio-gene Technology
Most Recent Events
- 24 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2023 New trial record
- 26 Jun 2023 Status changed from not yet recruiting to recruiting.